Calcium and Vitamin D Got Demoted in the BMJ. The Trial Data Are More Stubborn Than the Headline.

The press release landed Sunday and the wires did what wires do. “Little benefit” ran the line, attached to a BMJ meta-analysis of 153,902 older adults; by the afternoon, the cheap white pill that more than half of American women over sixty take with breakfast had its tidy verdict. Calcium and vitamin D, the explainers said, were finally getting their comeuppance. Read the paper and the verdict softens at the edges, then keeps softening.

The arithmetic is plain enough. Across 69 randomized trials, calcium alone moved nothing. Vitamin D alone moved nothing. The combined-supplement arm, 15 trials and 51,126 participants, moved several things at once: a 9% relative reduction in any fracture (RR 0.91, 95% CI 0.84 to 0.99), a 13% reduction in nonvertebral fractures (RR 0.87, 0.78 to 0.96), and a 16% relative reduction in hip fractures (RR 0.84, 0.74 to 0.96). All three crossed statistical significance. None by a hair.

What the headline “little benefit” was actually doing, then, was carrying a clinical-meaningfulness judgment, not a statistical one. The authors decided in advance what an “important” hip-fracture reduction would look like, set the threshold at a 0.7% absolute risk reduction, and concluded the data didn’t clear it. Donal McNally, the bioengineering reader at Nottingham who reviewed the paper for the Science Media Centre, put the point as dryly as one can: “their choices might not be universally agreed.” Translated: a hip fracture in an 82-year-old kills about a quarter of them within a year and lands roughly 16% of the survivors in a nursing home she will not leave. The number you would have to dose to prevent one of those is not nothing if you happen to be the one.

The thinness underneath the pooled number is, if anything, more telling. Emma Duncan, the King’s College endocrinology professor, flagged the variable every clinician already knows matters most: “few studies provided baseline vitamin D levels.” Pool the deficient with the sufficient, the frail with the well, the institutionalized with the community-dwelling Floridian who walks three miles a day in the sun, ask whether the average bone benefits, and you get the answer this paper got. You also get the wrong answer for both groups.

Which is to say the paper is doing two things at once and the coverage is reporting only one. It is a genuine corrective to the assumption that a one-pill-fits-all bone strategy is worth its retail price for everyone over sixty-five, an assumption the USPSTF had already chipped at in 2018 when it recommended against routine low-dose supplementation for community-dwelling postmenopausal women. It is also a paper whose lead author, Olivier Massé, discloses payments from CPD Network, Ensemble IQ and Pharmascope, and whose press release stops at the pooled headline rather than the subgroup distinctions clinicians have spent thirty years asking about.

Co-author Guylène Thériault has the alternative ready: “exercise focusing on balance and strength,” “multicomponent interventions,” approaches that, in her words, do deliver meaningful reductions in risk. She is not wrong about the data. She is, perhaps, hopeful about the implementation. The reason the calcium pill became standard advice is that it is the intervention nursing homes, harried internists and homebound eighty-year-olds can actually pull off. Telling a frail patient with a vitamin D level of 18 ng/mL that what she really needs is a balance class on the second floor is the sort of advice that reads beautifully in a BMJ editorial and does nothing in a hallway in February.

Wall Street and wellness media want the verdict to be tidy: half a century of guidance overturned, the bone-pill aisle headed for a clearance sale. The paper gives a narrower answer. Combined calcium and vitamin D, in the pooled population studied here, produces a statistically robust reduction in fractures that the authors decided was not large enough to recommend. The populations for whom the benefit is likely largest, the deficient and the frail, were not separately characterized. The intervention proposed in its place, exercise programs in older adults, faces every implementation problem the white pill was invented to bypass.

A meta-analysis is a powerful tool for averaging. It is a poor tool for the patient in front of you. The reflex to declare half a century of guidance overturned by 153,902 averaged-together strangers is the same reflex that wrote the original guidance: certainty without granularity. The skeleton, as it happens, is still personal.

Sources

1. BMJ – Massé et al., calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis (2026)
2. Healio – Calcium, vitamin D supplements do not lower risk for fractures or falls (June 2026)
3. Science Media Centre – Expert reactions to the vitamin D and calcium meta-analysis
4. BMJ Group press release – Calcium and vitamin D supplements offer little to no meaningful benefit on fracture and fall prevention
5. USPSTF – Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults (2018)
6. NIH Office of Dietary Supplements – Vitamin D fact sheet (supplement-use prevalence in older Americans)
7. Time to Death and Nursing Home Admission in Older Adults with Hip Fracture: A Retrospective Cohort Study (PMC12693230)